Published in N Engl J Med on June 11, 2012
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN) | NCT00069784
Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria | NCT02035891
Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE) (RCT-IVVE) | NCT02762851
Canagliflozin-Mealtime Insulin Rescue | NCT02624908
Influenza Vaccine To Prevent Adverse Vascular Events:Pilot (IVVE:Pilot) | NCT01945268
Insulin Treatment in Diabetic Older People With Heart Failure. (Insulin-HF) | NCT03665350
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. START INVESTS P 13. N Engl J Med (2016) 7.04
Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes (2015) 2.87
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66
Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04
Is Hemoglobin A1c the Right Outcome for Studies of Diabetes? JAMA (2017) 2.03
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab (2013) 1.83
Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care (2012) 1.76
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab (2015) 1.47
Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia (2014) 1.42
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care (2016) 1.29
Year in diabetes 2012: The diabetes tsunami. J Clin Endocrinol Metab (2012) 1.19
Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial. Diabetes Care (2013) 1.18
Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care (2015) 1.10
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care (2014) 1.07
Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation (2014) 1.05
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
Barriers and solutions to diabetes management: An Indian perspective. Indian J Endocrinol Metab (2013) 1.03
Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 1.01
Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011. Diabetes Care (2015) 1.01
Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab (2014) 1.01
Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care (2013) 1.01
Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag (2014) 1.00
Interpreting adverse signals in diabetes drug development programs. Diabetes Care (2013) 0.99
Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. Diabetes Technol Ther (2013) 0.99
Diabetes and its comorbidities--where East meets West. Nat Rev Endocrinol (2013) 0.99
Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc (2014) 0.98
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig (2013) 0.98
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2016) 0.97
A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat Commun (2015) 0.97
Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care (2013) 0.97
Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol (2013) 0.97
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA (2016) 0.96
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol (2016) 0.94
Omega-3 index and cardiovascular health. Nutrients (2014) 0.94
The links between insulin resistance, diabetes, and cancer. Curr Diab Rep (2013) 0.92
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care (2013) 0.92
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes (2015) 0.92
We can change the natural history of type 2 diabetes. Diabetes Care (2014) 0.91
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J (2015) 0.91
Insulin therapy for pre-hyperglycemic beta-cell endoplasmic reticulum crowding. PLoS One (2013) 0.90
Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Ann Oncol (2013) 0.89
Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol (2013) 0.89
Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care (2013) 0.89
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. Diabetes Care (2015) 0.89
The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs (2014) 0.88
Insulin use early in the course of type 2 diabetes mellitus: the ORIGIN trial. Curr Diab Rep (2013) 0.88
Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai. PLoS One (2013) 0.88
Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE. Diabetes Ther (2012) 0.88
Insulin therapy and cancer. Diabetes Care (2013) 0.87
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2015) 0.86
HbA1c below 7 % as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol (2015) 0.86
Periprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention. Am J Cardiol (2014) 0.86
The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem (2013) 0.86
Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care (2013) 0.85
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care (2013) 0.85
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res (2015) 0.85
Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One (2012) 0.85
Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes (2015) 0.85
Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. PLoS One (2013) 0.85
Diabetes Dyslipidemia. Diabetes Ther (2016) 0.85
On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol (2014) 0.84
Preventing type 2 diabetes mellitus: a call for personalized intervention. Perm J (2013) 0.84
Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One (2014) 0.84
How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. Diabetes Care (2013) 0.84
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care (2013) 0.84
Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol (2015) 0.84
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation (2016) 0.84
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. Diabetes Ther (2015) 0.83
Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. Diabetes (2016) 0.83
Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab (2013) 0.83
Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: a partially double-blind, randomized, three-arm unicenter study. Cardiovasc Diabetol (2014) 0.83
Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse model. Breast Cancer Res (2015) 0.83
Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. Nat Rev Endocrinol (2013) 0.83
Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk. ISRN Endocrinol (2013) 0.83
Determinants and consequences of insulin initiation for type 2 diabetes in France: analysis of the National Health and Wellness Survey. Patient Prefer Adherence (2013) 0.83
Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. Endocr Connect (2015) 0.82
Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care (2016) 0.82
Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study. Cardiovasc Diabetol (2013) 0.82
Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis (2014) 0.82
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. BMC Med (2014) 0.82
Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol (2012) 0.82
Risk Prediction for Early CKD in Type 2 Diabetes. Clin J Am Soc Nephrol (2015) 0.82
Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device. Clinicoecon Outcomes Res (2013) 0.81
Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovasc Diabetol (2016) 0.81
Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Indian J Endocrinol Metab (2014) 0.81
Early insulinization to prevent diabetes progression. Diabetes Care (2013) 0.81
Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatr Diabetes (2015) 0.81
A dysglycaemic effect of statins in diabetes: relevance to clinical practice? Diabetologia (2014) 0.81
Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PLoS One (2013) 0.81
Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study. Cardiovasc Diabetol (2015) 0.80
Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". Clin Pharmacol Ther (2015) 0.80
One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Investig (2014) 0.80
Insulin analogs and cancer: a note of caution. Front Endocrinol (Lausanne) (2014) 0.80
Efficacy of intensive control of glucose in stroke prevention: a meta-analysis of data from 59,197 participants in 9 randomized controlled trials. PLoS One (2013) 0.80
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus. Curr Diab Rep (2016) 0.79
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care (2005) 7.07
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J (2007) 4.88
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73